Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced the appointment of Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. Dr. Kramer brings over 20 years of neuroscience-focused medical affairs leadership, having held senior roles at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie. His expertise is expected to support Helus in advancing its pipeline and strengthening engagement with clinical and scientific stakeholders.
The appointment comes as Helus Pharma progresses its lead candidate, HLP003, a proprietary NSA currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to address a significant unmet need. Additionally, the company is advancing HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder. Helus also maintains an extensive research portfolio of investigational NSAs aimed at improving mental health outcomes through neuroplasticity.
Dr. Kramer's track record includes leadership in developing and executing medical strategies for neuroscience therapies, which aligns with Helus's mission to improve the treatment landscape for depression, anxiety, and other mental health conditions. His role will involve overseeing medical affairs activities, including scientific communications, key opinion leader engagement, and real-world evidence generation. The company believes his experience will be instrumental as it navigates late-stage clinical development and prepares for potential commercialization.
Helus Pharma, the commercial operating name of Cybin Inc., operates in Canada, the United States, the United Kingdom, and Ireland. The company's proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, offering durable improvements in mental health. For more information, visit the company's website at www.helus.com or follow on social media platforms. The full press release is available at https://ibn.fm/FdEXH.
This appointment underscores Helus Pharma's commitment to building a strong leadership team as it advances its pipeline toward regulatory submissions and potential market entry. With Dr. Kramer's deep industry knowledge, the company is well-positioned to enhance its medical affairs capabilities and engage with the scientific community to support the development of its novel therapies.
